ClinicalTrials.gg
CompletedNCT02199691Updated Apr 4, 2022Results posted

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents

A Phase 2 interventional study of Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine and Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine in Meningitis, Meningococcal Meningitis and Meningococcal Infections, sponsored by Sanofi Pasteur, a Sanofi Company. Completed at 36 sites in 2 countries. Open to participants aged 10 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-04.

Primary conditionMeningitis, MeningococcalRegistry: MeningitisReclassifiedWhy we changed it
Registry
Meningitis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Meningitis, Meningococcal
Why
  1. The study's listed conditions name Meningitis, Meningococcal, a narrower term within Meningitis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,715
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Meningitis, Meningococcal by Sanofi — none open to participants now, none under way, none of them phase 3. Meningitis, Meningococcal · Sanofi.

Enrollment
3rd of 23
1,715 · median 907
Started
2014
the only one that year
Phase 2
6 of 24
none open now
Registered
9th of 24
by date

Among the 24 studies in Meningitis, Meningococcal by Sanofi, this one is the 3rd largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2014, is one of 6 in phase 2, and was the 9th registered.

Meningitis, Meningococcal

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

Browse Meningitis, Meningococcal studies →

Open to participants now

None of the 24 studies in Meningitis, Meningococcal by Sanofi is open now. The open studies under Meningitis, Meningococcal, anywhere →

Who these studies take

Of the 5 Meningitis, Meningococcal studies recruiting now, none set no upper age limit and 5 stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies in Meningitis, Meningococcal by Sanofi as a file.
02

Study summary

The purpose of the study was to evaluate the immunogenicity and describe the safety of Meningococcal Polysaccharide (Serogroups A, C, Y and W) Tetanus Toxoid (MenACYW) Conjugate vaccine compared to the licensed vaccine MENVEO® in adolescents 10 to 17 years of age in the United States (US). This study also evaluated the immunogenicity and safety of MenACYW Conjugate vaccine when given alone compared to when given concomitantly with tetanus, diphtheria, acellular pertussis (Tdap) vaccine and human papilloma virus (HPV) vaccine.

Primary objective:

  • To evaluate the antibody responses to the antigens present in MenACYW Conjugate vaccine when MenACYW Conjugate vaccine was given alone compared to those when MENVEO vaccine was given alone.

Secondary objective:

  • To evaluate the antibody responses to the antigens present in MenACYW Conjugate vaccine, when MenACYW Conjugate vaccine was given concomitantly with Tdap and HPV vaccines, compared to those when it was given alone.
  • To evaluate the antibody responses to the antigens present in Tdap vaccine, when Tdap vaccine was given concomitantly with MenACYW Conjugate vaccine and HPV vaccine, compared to those when Tdap vaccine was given with HPV vaccine only.
  • To evaluate the antibody responses to the antigens present in HPV vaccine after the 3-dose series, when the first dose of HPV vaccine is given concomitantly with MenACYW Conjugate vaccine and Tdap vaccine, compared to those when the first dose of HPV vaccine is given with Tdap vaccine only.

Observational objective:

  • To describe the safety profile of MenACYW Conjugate vaccine, compared to that of the licensed vaccine MENVEO®, and when MenACYW Conjugate vaccine was given with Tdap and HPV vaccines.
Read the detailed description

Healthy adolescents were randomized and received a single dose of their assigned vaccines. They were assessed for immunogenicity at baseline (pre-vaccination) and at 30 days post-vaccination. Safety information were collected post-vaccination and throughout the entire study.

03

Conditions studied

  • Meningitis
  • Meningococcal Meningitis
  • Meningococcal Infections

Browse trials for

Keywords

  • Meningitis
  • Meningococcal Meningitis
  • MenACYW Conjugate vaccine
  • MENVEO vaccine
  • Adacel®
  • GARDASIL®
04

In context

Meningitis, Meningococcal Reclassified

125 studies on the registry are indexed under Meningitis, Meningococcal; 10 are open to participants now.

This study's enrollment of 1,715 is above the median of 538 across 113 interventional studies indexed under Meningitis, Meningococcal.

Browse Meningitis, Meningococcal studies →

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Compared within Meningitis, Meningococcal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Meningitis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 10 to 17 years on the day of inclusion.
  • form was signed and dated by the parent(s) or another legally acceptable representative.
  • Assent form was signed and dated by the participant.
  • Participant and parent legally acceptable representative were able to attend all scheduled visits and comply with all trial procedures.

Exclusion criteria

Exclusion Criteria:

  • Participant was pregnant, or lactating, or of (to be considered of non-childbearing potential, a female must be pre-menarche, surgically sterile, or using an effective method of or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination).
  • Participation in the 4 weeks preceding the first trial vaccination(s) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
  • Receipt of any vaccine in the 4 weeks preceding the first trial vaccination(s) or planned receipt of any vaccine in the 4 weeks prior to or following any trial vaccination except for influenza vaccination, which may be received at least 2 weeks before or after any study vaccines. This exception included monovalent influenza vaccines and multivalent influenza vaccines.
  • Previous vaccination against meningococcal disease with either the trial vaccine or any mono- or polyvalent polysaccharide or conjugate meningococcal vaccine containing A, C, W, or Y antigens.
  • History of vaccination with any tetanus, diphtheria, or pertussis vaccine within the previous 4 years.
  • Previous human papilloma virus (HPV) vaccination.
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months.
  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
  • History of meningococcal infection, confirmed either clinically, serologically, or microbiologically.
  • At high risk for meningococcal infection during the trial (i.e., participants with persistent complement deficiency, with anatomic or functional asplenia, or participants travelling to countries with high endemic or epidemic disease).
  • Known systemic to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances, including encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of administration of a previous pertussis antigen-containing vaccine.
  • Personal history of Guillain-Barré syndrome.
  • Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid-containing vaccine within at least 10 years of the proposed study vaccination.
  • Verbal report of thrombocytopenia, contraindicating intramuscular vaccination.
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination.
  • Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
  • Current alcohol abuse or drug addiction.
  • Chronic illness (e.g., [HIV] , ) that, in the opinion of the investigator, was at a stage where it might interfere with trial conduct or completion.
  • Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature >= 100.4 degree fahrenheit [°F]). A prospective participant was not included in the study until the condition had resolved or the febrile event had subsided.
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw.
  • Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,715 participants (actual)

Study arms

  • Experimental
    Group 1: MenACYW Conjugate Vaccine

    Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine on Day 0.

    Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine

  • Active comparator
    Group 2: MENVEO® Vaccine

    Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MENVEO® vaccine on Day 0.

    Biological: Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine

  • Experimental
    Group 3: MenACYW Conjugate Vaccine+Tdap+HPV

    Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of MenACYW Conjugate vaccine, Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap), and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.

    Biological: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed · Biological: GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant · Biological: Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine

  • Active comparator
    Group 4: Tdap+HPV

    Healthy, meningococcal-vaccine naïve participants aged 10 to 17 years received a single dose of Tdap and Dose 1 of HPV Vaccine on Day 0. HPV Vaccine Dose 2 and Dose 3 were given at 2 and 6 months, respectively, after Dose 1 given on Day 0.

    Biological: Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed · Biological: GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant

Interventions

07

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine

    Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers greater than or equal to (\>=) 1:8 for participants with pre-vaccination hSBA titers less than (\<) 1:8 or at least a 4-fold increase in hSBA titers from pre- to post vaccination for participants with pre-vaccination hSBA titers \>= 1:8. Data for this outcome measure was not planned to be collected and analyzed for Group 4:Tdap+HPV.

    Time frame: Day 30 (post-vaccination)

Secondary outcomes

  1. Percentage of Participants Achieving hSBA Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines

    Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:8 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post vaccination for participants with pre-vaccination hSBA titers \>= 1:8.

    Time frame: Day 30 (post-vaccination on Day 0)

  2. Geometric Mean Concentrations (GMCs) of PT, FHA, PRN, and FIM Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines

    Anti-Pertussis toxoid (PT), Filamentous hemagglutinin (FHA), Pertactin (PRN), and Fimbriae types 2 and 3 (FIM) antibodies were measured by enzyme-linked immunosorbent assay (ELISA).

    Time frame: Day 30 (post-vaccination on Day 0)

  3. Percentage of Participants Achieving Anti-Tetanus and Anti-Diphtheria Concentrations >= 1.0 International Unit (IU)/mL Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines

    Anti-Diphtheria antibodies were measured by a toxin neutralization test. Anti-Tetanus antibodies were measured by ELISA.

    Time frame: Day 30 (post-vaccination on Day 0)

  4. Percentage of Participants Achieving Seroconversion for Anti-HPV6, HPV11, HPV16, and HPV18 Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines

    Anti-HPV 6, 11, 16, and 18 antibodies were measured using a competitive Luminex immunoassay. Seroconversion was defined as changing serostatus from seronegative to seropositive. Cutoff values for HPV seropositivity were \>= 20 milli-Merck units per milliliter (mMU/mL) for types 6 and 16, \>= 16 mMU/mL for type 11, and \>= 24mMU/mL for type 18.

    Time frame: Day 210 (post-vaccination on Day 0)

  5. Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With MenACYW Conjugate Vaccine or MENVEO® Vaccine at Day 0: Group 1 and Group 2

    A Solicited Reaction (SR) was an Adverse Event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions included: Pain, Erythema, and Swelling.

    Time frame: Within 7 days after vaccines injections at Day 0

  6. Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines at Day 0: Group 3

    A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions included: Pain, Erythema, and Swelling.

    Time frame: Within 7 days after vaccines injections at Day 0

  7. Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With Tdap and HPV Vaccines at Day 0: Group 4

    A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions included: Pain, Erythema, and Swelling.

    Time frame: Within 7 days after vaccines injections at Day 0

08

Results

Posted Jun 9, 2020

Participant flow

Study participants were enrolled in 40 centers in the Unites States (US) from 22 July 2014 to 25 February 2015.

Participant flow — Overall Study
MilestoneGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO® VaccineGroup 3: MenACYW Conjugate Vaccine+Tdap+HPVGroup 4: Tdap+HPV
Started505507403300
Safety analysis set (safas)503501392296
Completed495500376270
Not completed1072730
Withdrew: Protocol violation3367
Withdrew: Withdrawal by subject531213
Withdrew: Lost to follow-up21910

Outcome measures

PrimaryPercentage of Participants Achieving Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine

Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers greater than or equal to (\>=) 1:8 for participants with pre-vaccination hSBA titers less than (\<) 1:8 or at least a 4-fold increase in hSBA titers from pre- to post vaccination for participants with pre-vaccination hSBA titers \>= 1:8. Data for this outcome measure was not planned to be collected and analyzed for Group 4:Tdap+HPV.

Time frame:
Day 30 (post-vaccination)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Vaccine Seroresponse Measured by Serum Bactericidal Assay Using Human Complement (hSBA) Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MENVEO® Vaccine
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO® Vaccine
Serogroup A75.6 (71.4 to 79.4)66.4 (61.9 to 70.7)
Serogroup C97.2 (95.2 to 98.5)72.6 (68.3 to 76.6)
Serogroup Y97.0 (95.0 to 98.3)80.8 (76.9 to 84.3)
Serogroup W86.2 (82.7 to 89.2)66.6 (62.1 to 70.9)
Statistical analysis
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO® Vaccine · Percentage difference: 9.2 · 95% CI 3.4 to 15
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO® Vaccine · Percentage difference: 24.6 · 95% CI 20.3 to 29
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO® Vaccine · Percentage difference: 16.2 · 95% CI 12.3 to 20.2
  • Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO® Vaccine · Percentage difference: 19.6 · 95% CI 14.2 to 24.8
SecondaryPercentage of Participants Achieving hSBA Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines

Antibody titers against meningococcal serogroups A, C, Y, and W measured by hSBA. The hSBA vaccine seroresponse for serogroups A, C, Y, and W was defined as post-vaccination hSBA titers \>= 1:8 for participants with pre-vaccination hSBA titers \< 1:8 or at least a 4-fold increase in hSBA titers from pre- to post vaccination for participants with pre-vaccination hSBA titers \>= 1:8.

Time frame:
Day 30 (post-vaccination on Day 0)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving hSBA Vaccine Seroresponse Against Meningococcal Serogroups A, C, Y, and W Following Vaccination With Either MenACYW Conjugate Vaccine or MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines
percentage of participantsGroup 1: MenACYW Conjugate VaccineGroup 3: MenACYW Conjugate Vaccine+Tdap+HPV
Serogroup A75.680.6
Serogroup C97.297.2
Serogroup Y97.095.6
Serogroup W86.283.9
Statistical analysis
  • Group 1: MenACYW Conjugate Vaccine vs Group 3: MenACYW Conjugate Vaccine+Tdap+HPV · Percentage difference: 5 · 95% CI -0.8 to 10.5
  • Group 1: MenACYW Conjugate Vaccine vs Group 3: MenACYW Conjugate Vaccine+Tdap+HPV · Percentage difference: 0 · 95% CI -2.5 to 2.4
  • Group 1: MenACYW Conjugate Vaccine vs Group 3: MenACYW Conjugate Vaccine+Tdap+HPV · Percentage difference: -1.4 · 95% CI -4.3 to 1.2
  • Group 1: MenACYW Conjugate Vaccine vs Group 3: MenACYW Conjugate Vaccine+Tdap+HPV · Percentage difference: -2.3 · 95% CI -7.3 to 2.6
SecondaryGeometric Mean Concentrations (GMCs) of PT, FHA, PRN, and FIM Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines

Anti-Pertussis toxoid (PT), Filamentous hemagglutinin (FHA), Pertactin (PRN), and Fimbriae types 2 and 3 (FIM) antibodies were measured by enzyme-linked immunosorbent assay (ELISA).

Time frame:
Day 30 (post-vaccination on Day 0)
Reported as:
Geometric mean · ELISA units (EU)/mL
Geometric Mean Concentrations (GMCs) of PT, FHA, PRN, and FIM Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines
ELISA units (EU)/mLGroup 3: MenACYW Conjugate Vaccine+Tdap+HPVGroup 4: Tdap+HPV
Anti-Pertussis toxoid (PT)37.5 (33.8 to 41.7)44.4 (39.5 to 49.9)
Filamentous hemagglutinin (FHA)180 (168 to 194)242 (218 to 268)
Pertactin (PRN)200 (177 to 225)265 (231 to 304)
Fimbriae types 2 and 3 (FIM)339 (285 to 403)499 (414 to 601)
Statistical analysis
  • Group 3: MenACYW Conjugate Vaccine+Tdap+HPV vs Group 4: Tdap+HPV · Geometric mean ratio: 0.845 · 95% CI 0.722 to 0.99
  • Group 3: MenACYW Conjugate Vaccine+Tdap+HPV vs Group 4: Tdap+HPV · Geometric mean ratio: 0.746 · 95% CI 0.661 to 0.842
  • Group 3: MenACYW Conjugate Vaccine+Tdap+HPV vs Group 4: Tdap+HPV · Geometric mean ratio: 0.753 · 95% CI 0.627 to 0.903
  • Group 3: MenACYW Conjugate Vaccine+Tdap+HPV vs Group 4: Tdap+HPV · Geometric mean ratio: 0.679 · 95% CI 0.525 to 0.878
SecondaryPercentage of Participants Achieving Anti-Tetanus and Anti-Diphtheria Concentrations >= 1.0 International Unit (IU)/mL Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines

Anti-Diphtheria antibodies were measured by a toxin neutralization test. Anti-Tetanus antibodies were measured by ELISA.

Time frame:
Day 30 (post-vaccination on Day 0)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Anti-Tetanus and Anti-Diphtheria Concentrations >= 1.0 International Unit (IU)/mL Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines
percentage of participantsGroup 3: MenACYW Conjugate Vaccine+Tdap+HPVGroup 4: Tdap+HPV
Diphtheria97.8 (95.7 to 99.0)98.9 (96.7 to 99.8)
Tetanus99.7 (98.5 to 100.0)99.6 (97.9 to 100.0)
Statistical analysis
  • Group 3: MenACYW Conjugate Vaccine+Tdap+HPV vs Group 4: Tdap+HPV · Percentage difference: -1.1 · 95% CI -3.3 to 1.3
  • Group 3: MenACYW Conjugate Vaccine+Tdap+HPV vs Group 4: Tdap+HPV · Percentage difference: 0.1 · 95% CI -1.2 to 1.9
SecondaryPercentage of Participants Achieving Seroconversion for Anti-HPV6, HPV11, HPV16, and HPV18 Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines

Anti-HPV 6, 11, 16, and 18 antibodies were measured using a competitive Luminex immunoassay. Seroconversion was defined as changing serostatus from seronegative to seropositive. Cutoff values for HPV seropositivity were \>= 20 milli-Merck units per milliliter (mMU/mL) for types 6 and 16, \>= 16 mMU/mL for type 11, and \>= 24mMU/mL for type 18.

Time frame:
Day 210 (post-vaccination on Day 0)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Seroconversion for Anti-HPV6, HPV11, HPV16, and HPV18 Antibodies Following Vaccination With Either MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines or Tdap and HPV Vaccines
percentage of participantsGroup 3: MenACYW Conjugate Vaccine+Tdap+HPVGroup 4: Tdap+HPV
HPV Type 697.5 (94.7 to 99.1)95.7 (91.4 to 98.3)
HPV Type 1199.6 (97.7 to 100.0)98.8 (95.7 to 99.9)
HPV Type 1699.2 (97.0 to 99.9)98.8 (95.7 to 99.9)
HPV Type 1899.2 (97.0 to 99.9)98.8 (95.7 to 99.9)
Statistical analysis
  • Group 3: MenACYW Conjugate Vaccine+Tdap+HPV vs Group 4: Tdap+HPV · Percentage difference: 1.8 · 95% CI -1.8 to 6.3
  • Group 3: MenACYW Conjugate Vaccine+Tdap+HPV vs Group 4: Tdap+HPV · Percentage difference: 0.8 · 95% CI -1.3 to 3.9
  • Group 3: MenACYW Conjugate Vaccine+Tdap+HPV vs Group 4: Tdap+HPV · Percentage difference: 0.4 · 95% CI -1.9 to 3.6
  • Group 3: MenACYW Conjugate Vaccine+Tdap+HPV vs Group 4: Tdap+HPV · Percentage difference: 0.4 · 95% CI -1.9 to 3.6
SecondaryNumber of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With MenACYW Conjugate Vaccine or MENVEO® Vaccine at Day 0: Group 1 and Group 2

A Solicited Reaction (SR) was an Adverse Event (AE) that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions included: Pain, Erythema, and Swelling.

Time frame:
Within 7 days after vaccines injections at Day 0
Reported as:
Count of participants · Participants
Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With MenACYW Conjugate Vaccine or MENVEO® Vaccine at Day 0: Group 1 and Group 2
ParticipantsGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO® Vaccine
Pain224209
Erythema2537
Swelling2732
SecondaryNumber of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines at Day 0: Group 3

A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions included: Pain, Erythema, and Swelling.

Time frame:
Within 7 days after vaccines injections at Day 0
Reported as:
Count of participants · Participants
Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With MenACYW Conjugate Vaccine Given With Tdap and HPV Vaccines at Day 0: Group 3
ParticipantsGroup 3: MenACYW Conjugate Vaccine+Tdap+HPV
MenACYW site: Pain183
MenACYW site: Erythema15
MenACYW site: Swelling17
Tdap site: Pain286
Tdap site: Erythema28
Tdap site: Swelling24
HPV site: Pain288
HPV site: Erythema31
HPV site: Swelling26
SecondaryNumber of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With Tdap and HPV Vaccines at Day 0: Group 4

A SR was an AE that was prelisted (i.e., solicited) in the electronic case report form (eCRF) and considered to be related to vaccination (adverse drug reaction). Solicited injection site reactions included: Pain, Erythema, and Swelling.

Time frame:
Within 7 days after vaccines injections at Day 0
Reported as:
Count of participants · Participants
Number of Participants Reporting Solicited Injection Site Reactions (Pain, Erythema, Swelling) Following Vaccination With Tdap and HPV Vaccines at Day 0: Group 4
ParticipantsGroup 4: Tdap+HPV
Tdap site: Pain211
Tdap site: Erythema14
Tdap site: Swelling20
HPV site: Pain201
HPV site: Erythema16
HPV site: Swelling23

Adverse events

Collected over Adverse event (AE) data were collected from Day 0 (post-vaccination) up to 30 days after last vaccination. SR data were collected within 7 days after any vaccination. Serious adverse events (SAEs) data were collected throughout the study (up to 180 days after vaccination for Group 1 and 2, and up to 210 days after vaccination on Day 0 for Group 3 and 4).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: MenACYW Conjugate Vaccine0/503 (0%)4/503 (0.8%)331/503 (65.8%)
Group 2: MENVEO® Vaccine0/501 (0%)4/501 (0.8%)337/501 (67.3%)
Group 3: MenACYW Conjugate Vaccine+Tdap+HPV0/392 (0%)4/392 (1%)348/392 (88.8%)
Group 4: Tdap+HPV0/296 (0%)4/296 (1.4%)263/296 (88.9%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO® VaccineGroup 3: MenACYW Conjugate Vaccine+Tdap+HPVGroup 4: Tdap+HPV
AppendicitisInfections and infestations0/5031/5010/3922/296
Staphylococcal Scalded Skin SyndromeInfections and infestations0/5030/5010/3921/296
Suicidal IdeationPsychiatric disorders0/5030/5011/3921/296
HypothyroidismEndocrine disorders0/5030/5011/3920/296
ConvulsionNervous system disorders1/5030/5011/3920/296
AsthmaRespiratory, thoracic and mediastinal disorders0/5030/5011/3920/296
Abnormal BehaviourPsychiatric disorders0/5031/5010/3920/296
Major DepressionPsychiatric disorders0/5031/5010/3920/296
Erythema MultiformeSkin and subcutaneous tissue disorders0/5031/5010/3920/296
FaecalomaGastrointestinal disorders1/5030/5010/3920/296
Most frequent other events
Most frequent other events
EventGroup 1: MenACYW Conjugate VaccineGroup 2: MENVEO® VaccineGroup 3: MenACYW Conjugate Vaccine+Tdap+HPVGroup 4: Tdap+HPV
Injection Site PainGeneral disorders224/503209/501327/392234/296
MyalgiaMusculoskeletal and connective tissue disorders175/503173/501239/392161/296
HeadacheNervous system disorders155/503159/501137/39287/296
MalaiseGeneral disorders130/503131/501113/39281/296
Injection Site ErythemaGeneral disorders25/50337/50144/39224/296
Injection Site SwellingGeneral disorders27/50332/50142/39232/296
Upper Respiratory Tract InfectionInfections and infestations24/50330/50127/39212/296
PharyngitisInfections and infestations15/50332/50122/39214/296

Baseline characteristics

Analysis was performed on all randomized participants.

Age, Continuous
Age, Continuous(years)Group 1: MenACYW Conjugate VaccineGroup 2: MENVEO® VaccineGroup 3: MenACYW Conjugate Vaccine+Tdap+HPVGroup 4: Tdap+HPVTotal
Mean11.4 ± 1.3911.4 ± 1.3911.3 ± 1.0611.4 ± 1.4111.4 ± 1.32
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: MenACYW Conjugate VaccineGroup 2: MENVEO® VaccineGroup 3: MenACYW Conjugate Vaccine+Tdap+HPVGroup 4: Tdap+HPVTotal
Female259232197144832
Male246275206156883
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: MenACYW Conjugate VaccineGroup 2: MENVEO® VaccineGroup 3: MenACYW Conjugate Vaccine+Tdap+HPVGroup 4: Tdap+HPVTotal
American Indian or Alaska Native30418
Asian33118
Native Hawaiian or Other Pacific Islander122510
Black or African American3022151885
White4424563612611520
More than one race2624201282
Unknown or Not Reported00022
Region of Enrollment
Region of Enrollment(Participants)Group 1: MenACYW Conjugate VaccineGroup 2: MENVEO® VaccineGroup 3: MenACYW Conjugate Vaccine+Tdap+HPVGroup 4: Tdap+HPVTotal
United States5055074033001715
09

Study locations

36 sites
  • Birmingham, Alabama 35235, United States
  • Huntsville, Alabama 35802, United States
  • Downey, California 90241, United States
  • San Diego, California 92103, United States
  • Miami Beach, Florida 33141, United States
  • Wichita, Kansas 67205, United States
  • Bardstown, Kentucky 40004, United States
  • Nicholasville, Kentucky 40356, United States
  • Columbia, Maryland 21075, United States
  • Lincoln, Nebraska 68504, United States
  • Lincoln, Nebraska 68505, United States
  • Lincoln, Nebraska 68516, United States
  • Cleveland, Ohio 44121, United States
  • Dayton, Ohio 45414, United States
  • Norman, Oklahoma 73069, United States
  • Erie, Pennsylvania 16505, United States
  • Charleston, South Carolina 29414, United States
  • Kingsport, Tennessee 37660, United States
  • Tullahoma, Tennessee 37388, United States
  • Layton, Utah 84041, United States
  • Orem, Utah 84057, United States
  • Payson, Utah 84651, United States
  • Provo, Utah 84064, United States
  • Roy, Utah 84067, United States
  • Salt Lake City, Utah 84109, United States
  • Salt Lake City, Utah 84124, United States
  • South Jordan, Utah 84095, United States
  • Spanish Fork, Utah 84660, United States
  • Syracuse, Utah 84075, United States
  • West Haven, Utah 84401, United States
  • West Jordan, Utah 84088, United States
  • Charlottesville, Virginia 22902, United States
  • Midlothian, Virginia 23113, United States
  • Spokane, Washington 99204, United States
  • Spokane, Washington 99218, United States
  • San Juan, 00918, Puerto Rico
10

References and documents

Publications

  • Chang LJ, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine. 2020 Apr 23;38(19):3560-3569. doi: 10.1016/j.vaccine.2020.03.017. Epub 2020 Mar 21. PubMed 32209248 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2014 to primary completion in Oct 2015, 14 months.

Results were first posted in Jun 2020, 4 years 8 months after primary completion. A results delay was requested in Sep 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2014
First posted
Jul 24, 2014
StartActual
Jul 22, 2014
Primary completionActual
Oct 2, 2015
CompletionActual
Oct 2, 2015
Results delay requested
Sep 29, 2015
Results first posted
Jun 9, 2020
Last update
Apr 4, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02199691
Responsible party
Sponsor
First posted
Jul 24, 2014
Start date
Jul 22, 2014
Primary completion
Oct 2, 2015
Completion
Oct 2, 2015
Results posted
Jun 9, 2020
Last update
Apr 4, 2022

Study contacts

Medical Director
study director · Sanofi Pasteur Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adacel · Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18

Start the discussion